InvestorsHub Logo
Followers 273
Posts 8597
Boards Moderated 0
Alias Born 10/05/2010

Re: None

Wednesday, 11/16/2016 7:47:16 AM

Wednesday, November 16, 2016 7:47:16 AM

Post# of 136
8K out today, not a lot of new info here that I was not aware of. I'll have to do some more research into the NuLife Technologies subsidiary to see exactly what that contains, I've really been focused on BioMed and Gandys research up to this point.

http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=11692962

It sounds like the asset purchase is basically a done deal.

On November 1, 2016, pursuant to, and in preparation for, the fulfillment of the Asset Purchase Agreement to acquire all of the assets of GandTex, LLC, a Texas limited liability company (“GandTex”), as disclosed by the Company on Form 8-K on October 17, 2016, the Company formed 2 subsidiaries in the state of Nevada, NuLife BioMed, Inc., and NuLife Technologies, Inc. GandTex is a biomedical company focused on advancing human organ transplant technology and medical research. The assets being transferred consist of certain proprietary patents for eliminating the need for an organ or tissue match, and the necessity for anti-rejection drugs, as well as management of, and historical data for, animal trials conducted by GandTex.



Concerning the convertible promissory notes mentioned in the filing, toxic financing is never a good thing, it's probably one of the most un-shareholder friendly things a company can do. However, it's one of the unfortunate things that happen in cash strapped micro-caps, which about 99% of them are, luckily these guys only have 2 $50K notes, that's not that bad IMO.

WELCOME TO